CRBP - Corbus Pharmaceuticals Holdings, Inc.
5.48 0.00 (0.00%)
After hours: 4:37PM EDT
| Previous Close | 5.60 |
| Open | 5.58 |
| Bid | 5.48 x 4000 |
| Ask | 5.49 x 3000 |
| Day's Range | 5.46 - 5.64 |
| 52 Week Range | 4.96 - 9.11 |
| Volume | 357,379 |
| Avg. Volume | 640,245 |
| Market Cap | 354.291M |
| Beta (3Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.93 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.57 |
- Simply Wall St.
Health Check: How Prudently Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Investopedia
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- Thomson Reuters StreetEvents
Edited Transcript of CRBP earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call
- Simply Wall St.
Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Motley FoolCorbus Pharmaceuticals Holdings, Inc. (CRBP) Q2 2019 Earnings Call Transcript
CRBP earnings call for the period ending June 30, 2019.
- GuruFocus.com
Corbus Pharmaceuticals Holdings Inc (CRBP) COO Robert Paul Discordia Bought $87,900 of Shares
COO of Corbus Pharmaceuticals Holdings Inc (30-Year Financial, Insider Trades) Robert Paul Discordia (insider trades) bought 15,000 shares of CRBP on 08/12/2019 at an average price of $5.86 a share. Continue reading...
- Motley Fool
What You'll Want to Know About Corbus Pharmaceuticals' Q2 Results
A licensing agreement enabled the clinical-stage biotech to report a big jump in revenue and a nice profit in Q2.
- Zacks
Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU.
- Simply Wall St.
How Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Can Impact Your Portfolio Volatility
Anyone researching Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) might want to consider the historical...
- Zacks
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
- CNW Group
Horizons ETFs Rebalances Marijuana-Focused ETFs
Horizons ETFs Rebalances Marijuana-Focused ETFs
- MarketWatch
Money flows in 17 popular marijuana stocks show fewer ‘short squeezes’
Prior low-level convictions for marijuana possession will be pardoned. Amid this news, one would expect marijuana stocks to run higher, but that’s not happening. Just like a doctor does X-rays to see what is going on inside the human body, investors can do an X-ray of marijuana stocks to figure out what is really going on.
- GlobeNewswire
Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or.
- Investopedia
Understanding Medical Cannabis vs. Recreational Cannabis Stocks
Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.
- GlobeNewswire
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis.
- Business Wire
Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019.
- GlobeNewswire
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
Norwood, MA, May 29, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
- GlobeNewswire
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation.
- Simply Wall St.
Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay Compare Well With Peers?
Yuval Cohen became the CEO of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in 2014. First, this article will...
- Motley Fool
Is Corbus Pharmaceuticals a Buy Now?
Here's what investors need to know about this company's synthetic cannabinoid.
- GlobeNewswire
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
Norwood, MA, May 15, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
- GlobeNewswire
SHAREHOLDER ALERT: CRBP FSNN MWA AAPL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, May 13, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire
CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action
NEW YORK, May 13, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
